



**HAL**  
open science

# Cerebral aspergillosis in the era of new antifungals: the CEREALS national cohort study Nationwide CEREBral Aspergillosis Lesional study (CEREALS)

A Serris, J Benzakoun, F Danion, R Porcher, R Sonnevile, M Wolff, S Kremer, V Letscher-Bru, A Fekkar, G Hekimian, et al.

## ► To cite this version:

A Serris, J Benzakoun, F Danion, R Porcher, R Sonnevile, et al.. Cerebral aspergillosis in the era of new antifungals: the CEREALS national cohort study Nationwide CEREBral Aspergillosis Lesional study (CEREALS). *Journal of Infection*, 2022, 84 (2), pp.227-236. 10.1016/j.jinf.2021.11.014. hal-03468425

**HAL Id: hal-03468425**

**<https://hal.science/hal-03468425v1>**

Submitted on 7 Jan 2022

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License

**Cerebral aspergillosis in the era of new antifungals : the CEREALS national cohort study****Nationwide CEREBral Aspergillosis Lesional study (CEREALS)**

A. Serris<sup>1</sup> MD-PhD, J. Benzakoun<sup>2\*</sup> MD, F. Danion<sup>3\*</sup> MD-PhD, R. Porcher<sup>4</sup> MD-PhD, R. Sonnevile<sup>5</sup> MD-PhD, M. Wolff<sup>6</sup> MD-PhD, S. Kremer<sup>7</sup> MD, V Letscher-Bru<sup>8</sup> MD, A Fekkar<sup>9</sup> MD, G. Hekimian<sup>10</sup> MD, V. Pourcher<sup>11</sup> MD-PhD, M-E. Bougnoux<sup>12</sup> MD-PhD, S. Poirée<sup>13</sup> MD, F. Ader<sup>14</sup> MD-PhD, F. Persat<sup>15</sup> MD-PhD, F. Cotton<sup>16,17</sup> MD-PhD, P. Tattevin<sup>18</sup> MD-PhD, J-P. Gangneux<sup>19</sup> MD-PhD, L. Lelièvre<sup>20</sup> MD, S. Cassaing<sup>21</sup> MD-PhD, Fabrice Bonneville<sup>22</sup> MD-PhD, S. Houze<sup>23</sup> MD-PhD, S. Bretagne<sup>24,25</sup> MD-PhD, R. Herbrecht<sup>26</sup> MD-PhD, O. Lortholary<sup>1,27¶</sup> MD-PhD, O. Naggara<sup>2¶</sup> MD-PhD, F. Lanternier<sup>1,24</sup> MD-PhD, and the CEREAL study group<sup>ψ</sup>

<sup>1</sup>Centre for Infectious Diseases and Tropical Medicine, Hôpital Universitaire Necker-Enfants Malades, Assistance Publique – Hôpitaux de Paris, Université de Paris, Paris, France

<sup>2</sup>Department of Neuroradiology, Université Paris-Descartes, Université de Paris, INSERM UMR 1266, GHU Paris, Hôpital Sainte-Anne, DHU Neurovasc Paris Sorbonne, Paris, France

<sup>3</sup>CHU de Strasbourg, Department of Infectious Diseases, Université de Strasbourg, Strasbourg, France

<sup>4</sup>Clinical Epidemiology Centre, Hôtel-Dieu Hospital, AP-HP and Centre of Research in Epidemiology and Statistics (CRESS), Institut National de la Santé et de la Recherche Médicale U1153; Université de Paris, Paris, France

<sup>5</sup>Intensive Care Medicine and Infectious Diseases, AP-HP, Bichat Hospital, and UMR1148, LVTS, Sorbonne Paris Cité, INSERM/Paris Diderot University, Paris, France

<sup>6</sup>Neurological Intensive Care Unit, Hôpital Sainte-Anne, GHU Paris Psychiatrie et NeuroSciences, Paris, France

<sup>7</sup>Department of Neuroradiology, Strasbourg University hospital, Engineering science, computer science and imaging laboratory (ICube), UMR 7357, University of Strasbourg-CNRS, Strasbourg, France

<sup>8</sup>Parasitology-Mycology Laboratory, Strasbourg University hospital, Strasbourg, France.

<sup>9</sup>Parasitology Mycology, Pitié-Salpêtrière Hospital, Paris, France

<sup>10</sup>Medical Intensive Care Unit, Assistance Publique-Hôpitaux de Paris, Pitié-Salpêtrière Hospital, France.

<sup>11</sup>Infectious Diseases Department, Assistance Publique-Hôpitaux de Paris, Pitié-Salpêtrière Hospital, France

<sup>12</sup>Parasitology-Mycology Laboratory, Hôpital Universitaire Necker-Enfants Malades, Assistance Publique – Hôpitaux de Paris, Paris, France

<sup>13</sup>Department of adult radiology, Hôpital Universitaire Necker-Enfants Malades, Assistance Publique – Hôpitaux de Paris, Paris, France

<sup>14</sup>Infectious Diseases department, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France.

<sup>15</sup>Parasitology-Mycology Laboratory, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France

<sup>16</sup>Department of Radiology, Lyon Sud Hospital, Hospices Civils de Lyon, Lyon, France

<sup>17</sup>CREATIS, CNRS UMR 5220 & Inserm U1044, Université Claude Bernard Lyon 1, Villeurbanne, France

<sup>18</sup>Infectious Diseases and Intensive Care Unit, Pontchaillou University Hospital, Rennes, France.

<sup>19</sup>Department of Mycology, Rennes University Hospital, Rennes, France

<sup>20</sup>Department of Infectious and Tropical Diseases, Toulouse University Hospital, Toulouse, France

<sup>21</sup>Department of Parasitology Mycology, Toulouse University Hospital, Toulouse, France

<sup>22</sup>Department of Neuroradiology, Toulouse University Hospital, Toulouse, France

<sup>23</sup>Mycology Parasitology Department, Bichat Hospital, Assistance Publique – Hôpitaux de Paris, Paris, France

<sup>24</sup>Molecular Mycology Unit, UMR2000, Centre National de la Recherche Scientifique (CNRS), Institut Pasteur, Paris, France

<sup>25</sup>Parasitology-Mycology Laboratory, Lariboisière, Saint-Louis, Fernand Widal Hospitals, Assistance Publique-Hôpitaux de Paris (AP-HP), Université de Paris, Paris, France

<sup>26</sup>Department of Haematology, Institut de Cancérologie de Strasbourg (ICANS), Strasbourg, France

<sup>27</sup>Molecular Mycology Unit, National Reference Centre for Invasive Mycoses and Antifungals, CNRS UMR 2000, Institut Pasteur, Paris, France.

**Correspondence:** fanny.lanternier@aphp.fr

\* both authors contributed equally to the work.

<sup>¶</sup> both authors contributed equally to the work.

<sup>Ψ</sup>CEREAL Study Group: Samy Ammari (Villejuif), Adela Angoulvant (Kremlin-Bicêtre), René Anxionnat (Nancy), Charlotte Barbier (Caen), Philippe Blanche (Hôpital Cochin, Paris), Julie Bonhomme (Caen), Françoise Botterel (Créteil), Thorsten Braun (Bobigny), Pierre-Yves Brillet

(Bobigny), Sophie Brun (Bobigny), Clémentine Charles (Lille), Cyril Chivot (Amiens), Taieb Chouaki (Amiens), Jean Michel Colombani (Clichy), Jean-Philippe Cottier (Tours), Eric Dannaoui (Hôpital Pitié Salpêtrière, Paris), Guillaume Desoubeaux (Tours), Denis Ducreux (Kremlin-Bicêtre), Mathieu Dupont (St Malo), Odile Eloy (Versailles), François Eugene (Rennes), Loïc Favennec (Rouen), Jamilé Frayer (Meaux), Sophie Gallas (Créteil), Jean-Pierre Gangneux (Rennes), David Guez (Villejuif), Gaëlle Guillerm (Brest), Elie Haddad (Hôpital Pitié Salpêtrière, Paris), Philippe Halimi (Paris), Lilia Hasseine (Nice), Gregory Kuchcinski (Lille), Jean-Philippe Lanoix (Amiens), Marie-Pierre Ledoux (Strasbourg), Agnès Lefort (Clichy), Liem Binh Luong Nguyen (Hôpital Cochin, Paris), Elias Mahdjoub (Hôpital Bichat, Paris), Aude Marie-Cardine (Rouen), Armand Mekontso Dessap (Créteil), André Paugam (hôpital Cochin, Paris), Juliette Pavie (Hôpital Européen Georges Pompidou, Paris), Nadya Pyatigorskaya (Paris), Marie-Pierre Revel (Hôpital Cochin, Paris), Christine Robin (Créteil), Boualem Sendid (Lille), Jean-Philippe Talarmin (Quimper), Yacine Tandjaoui (Bobigny), Benjamin Terrier (Hôpital Cochin, Paris), Dominique Toubas (Reims), Renaud Vernon (Caen), Fanny Vuotto (Lille), Martine Wallon (Lyon), Benjamin Wyplosz (Bobigny).

**Key words** : cerebral aspergillosis, galactomannan, invasive fungal disease

## **Abstract**


**Background:** Cerebral aspergillosis (CA) is a life-threatening disease for which diagnosis and management remain challenging. Detailed analyses from large cohorts are lacking.

**Methods:** We included 119 cases of proven (n=55) or probable (n=64) CA diagnosed between 2006 and 2018 at 20 French hospitals. Data were collected at baseline and during follow-up. Cerebral imaging was reviewed centrally by two neuroradiologists.

**Results:** The most frequent underlying conditions were haematological malignancy (40%) and solid organ transplantation (29%). Galactomannan was detected in the serum of 64% of patients. In 75% of cases, at least one of galactomannan, *Aspergillus* PCR, and  $\beta$ -D-glucan was positive in the cerebrospinal fluid. Six-week mortality was 45%. Two distinct patterns of disease were identified according to presumed route of dissemination. Presumed haematogenous dissemination (n=88) was associated with a higher frequency of impaired consciousness (64%), shorter time to diagnosis, the presence of multiple abscesses (70%), microangiopathy (52%), detection of serum galactomannan (69%) and *Aspergillus* PCR (68%), and higher six-week mortality (54%). By contrast, contiguous dissemination from the paranasal sinuses (n=31) was associated with a higher frequency of cranial nerve palsy (65%), evidence of meningitis on cerebral imaging (83%), macrovascular lesions (61%), delayed diagnosis, and lower six-week mortality (30%). In multivariate analysis and in a risk prediction model, haematogenous dissemination, haematological malignancy and the detection of serum galactomannan were associated with higher six-week mortality.

**Conclusion:** Distinguishing between hematogenous and contiguous dissemination patterns appears to be critical in the workup for CA, as they are associated with significant differences in clinical presentation and outcome.

## Graphical abstract



	<b>Haematogenous dissemination</b>	<b>Contiguous infection</b>
<b>Population characteristics</b>	median age: 56 y [44-62 y] Peculiar population : HM or SOT (77%)	median age: 68 y [55.5-77 y] Peculiar population : diabetes or no immunosuppression (39%)
<b>Median time between onset of symptoms and diagnosis</b>	2 days [0-9]	54 days [16-126]
<b>Mycology</b>	Positive assays for GM (69%) and <i>Aspergillus</i> PCR (68%) in serum	Negative assays GM (54%) and <i>Aspergillus</i> PCR (100%) in serum
<b>Radiological findings</b>	Abscesses (95%), often multiple (69%), with microangiopathy (52%)	Radiological meningitis (83%) and macrovascular lesions (61%)
<b>Mortality</b>	Higher (54% at W6, 69% at M12)	Lower (19% at W6, 46% at M12)

**Summary of clinical, mycological and radiological major characteristics of CA**

**Highlights :**

- Characteristics of cerebral aspergillosis vary according to the presumed route of *Aspergillus* dissemination to the brain
- Galactomannan antigen is positive in the sera in 61% of the patients and in the CSF in 69%
- CSF analysis is often informative and should be formed systematically if possible
- Cerebral ischemic events are reported in 2/3 of patients with cerebral aspergillosis with contiguous extension
- Cerebral aspergillosis mortality remains high (45% at W6 and 63% at M12)

## Introduction

Cerebral aspergillosis (CA) is one of the most severe forms of invasive aspergillosis (IA), and can occur after presumed haematogenous dissemination from an extra-cerebral site, by contiguous extension from an infection of the paranasal sinuses or the ears, or by direct inoculation (1). The majority of cases of CA reported in the literature concerns highly immunocompromised patients, such as neutropenic patients with haematological malignancy (HM) or solid organ transplant recipients (SOT) (2,3). There have also been reports of CA in moderately immunocompromised patients such as those with diabetes mellitus, and even in patients with no known risk factors (4,5). The clinical, radiological, and mycological features associated with the different underlying diseases or the route of dissemination to the brain (contiguous vs hematogenous) are poorly characterised. A few small series of cases have correlated brain Magnetic Resonance Imaging (MRI) patterns with the underlying immune status of CA patients (6,7). Data are also lacking on the efficacy of therapeutic strategies. Voriconazole and isavuconazole form the cornerstone of treatment, but the place of first-line dual therapy or of surgery and its timing in the treatment of CA remains a matter of debate (4,8–10).

We therefore conducted a nationwide study with the primary objective of assessing the impact of the presumed route of dissemination to the brain on the clinical and radiological presentation, as well as the six-week mortality in CA.

## Methods

### Type of study and data sources

We performed a retrospective study in France between January 2006 and December 2018: the CEREBRAL Aspergillosis Lesional study (CEREALS). Patients were identified through



mycologists, haematologists and specialists in infectious diseases or intensive care. Cases were identified at each participating centre, through physician notifications and cross-checking data with local microbiological databases. Clinical and radiological data were recorded on a standardised case report form. All brain computed tomography (CT) and/or MRI scans performed within 30 days before or after the diagnosis of CA and available were centrally reviewed by two neuroradiologists (JB and ON) blind to patient outcome.

### **Patients and definitions**

We included patients with proven or probable CA, as defined by the 2019 updated EORTC/MSG criteria, with the addition of diabetes mellitus as a host criterion (11). Proven CA was defined either as positive culture from the cerebrospinal fluid (CSF), a positive culture or histopathology from brain tissue with a positive tissue PCR results or, for patients with a sinus infection, histological evidence of invasive mold infection associated with growth of *Aspergillus* in culture from a sinus biopsy and imaging showing a continuity of the infection from the sinus to the brain. Probable CA was defined as focal brain lesions or meningeal enhancement on imaging associated either with the detection of GM in the CSF, or with proven or probable invasive extracerebral aspergillosis. As diabetes mellitus does not belong to EORTC/MSG host criteria, the qualification “modified probable” CA was retained in cases of diabetes being the only host criterion.

The presumed route of *Aspergillus* dissemination to the brain was classified as haematogenous or contiguous based on radiological data. We defined contiguous infections as those occurring as a result of the extension to the brain of a previously paranasal or ear infection, or occurring following facial trauma with radiological evidence of bone lysis. All other cases were considered as consequences of haematogenous dissemination.

**Underlying diseases:** Eight main underlying diseases were considered, with a single disease assigned to each patient, in the following order: haematological malignancy (HM) (including haematopoietic allogeneic stem cell transplantation), solid organ transplantation (SOT), diabetes mellitus, auto-immune or systemic inflammatory disease requiring corticosteroids or immunosuppressive treatment, a history of neurological or sinus surgery in the last three months, HIV infection, cirrhosis and primary immunodeficiency.

**Biological definitions:** Galactomannan antigen (GM) was considered “at diagnosis” when measured with 15 days prior or after CA diagnosis. It was considered positive above 0.5 in the sera and in the CSF. However, for the diagnosis of probable IA, a threshold of 1 was used, in accordance with the 2019 update of the EORTC/MSG criteria (11).  $\beta$ -D-glucan was considered positive when above 80 pg/mL in the sera or the CSF. Neutropenia was defined as a neutrophil count below  $500/\text{mm}^3$  and lymphopenia was defined as a lymphocyte count below  $1000/\text{mm}^3$ . Meningitis was defined as a CSF white blood cell count  $\geq 5/\text{mm}^3$ .

**Imaging:** The following imaging features were evaluated: type of dissemination (haematogenous vs. contiguous) according to lesion location, number, location and peripheral enhancement of abscesses, presence of ventriculitis, brain haematoma, ischemic lesions, lepto- and/or pachymeningitis (when post-contrast imaging was performed), presence and number of micro-bleeds (when T2\* or susceptibility-weighted images were performed) (see in supplementary methods for details definitions). Arterial stenosis or occlusion, arterial aneurysm were searched for on CT-Angiography or Time of Flight MR, when available. On imaging, abscesses were defined as limited intra- or extra-axial lesions with or without peripheral enhancement (wall enhancement). Brain infarct was defined as focal high intensity area without contrast enhancement on Diffusion-Weighted Imaging when available and/or lesions involving arterial territory hypodense on CT or hyperintense

on Fluid-attenuated Inversion Recovery (FLAIR) MRI. Small vessel disease was defined as the presence of  $\geq 5$  microbleeds in the absence of thrombopenia ( $<50$  G/L) or a history of high blood pressure and/or lacunar infarct and/or deep nucleus haematoma (17). Large vessel disease was defined as the presence of arterial stenosis and/or occlusion and/or large brain infarction involving arterial territory.

**Treatment definitions:** The first day of treatment was defined as the first day on which the patient received a drug active against *Aspergillus* spp. for the treatment of cerebral aspergillosis. Dual therapy was defined as treatment, for at least seven days, with two antifungal drugs active against *Aspergillus* spp.

### Statistical analysis

The primary outcome was 6-week mortality, with follow-up counted from the date of diagnosis of CA. It was treated as a binary outcome, with censoring before 6 weeks (1 patient) handled by weighting by the inverse probability of censoring (12). Missing baseline data were handled by multiple imputations based on chained equations, with 10 imputed datasets. Logistic regression was used to estimate the association of a set of predefined variables (age at diagnosis, sex, underlying disease, neutropenia at diagnosis, time from first symptoms to diagnosis, and detection of GM in serum) with 6-week mortality. The development and internal validation of the model are described in the supplementary material. Due to the limited number of events, we used different strategies for model building, based on backward variable selection. The final model is presented with odds ratios obtained after shrinkage and their 95% confidence intervals (95% CI). Given the exploratory objective of comparison between patients with hematogenous vs. contiguous extension, no correction for multiple testing was used. All tests were two-tailed, and  $p$  values of 0.05 or

less considered statistically significant. Analyses were performed with R statistical software version 3.6.3.

### **Ethical considerations**

The study was approved by the institutional review board of Necker-Enfants Malades Hospital (2017-AS-13) and was declared to the “Commission Nationale de l’Informatique et des Libertés” in accordance with French law. All clinical data were recorded anonymously.

### **Data Availability Statement**

Anonymized data will be shared by request from any qualified investigator.

## **RESULTS**

### **Patient characteristics**

In total, 119 patients with CA (54 proven, 65 probable) from 20 French hospitals were included in this study (figure 1). Seven patients receiving ibrutinib were reported in a previously published study (13). The main baseline characteristics of patients are presented in table 1.

Sixty-six per cent were male and median age at diagnosis was 58 years [47.5-66.5]. Seven patients were children. The most common underlying diseases were HM (n=47; 40%), followed by SOT (n=34; 29%), diabetes (n=10; 8%) and auto-immune diseases (n=8; 7%).

CA occurred by presumed haematogenous dissemination in 88 patients (74%) and by direct extension from a contiguous site in 31 patients (26%). Patients with haematogenous dissemination were younger ( $p<0.001$ ) and were more likely to have HM or SOT as a risk

factor ( $p<0.001$ ) than those with contiguous infection, which was more frequent in patients with diabetes mellitus ( $p=0.02$ ) or with no identified risk factor ( $p=0.009$ ).

### **Clinical presentation**

The clinical findings at diagnosis are presented in table 1. Sixty-four patients (54%) were hospitalised in an intensive care unit at the time of CA diagnosis.

Fever was present in 42% of the patients. The main neurological symptoms reported were impaired consciousness (46%), headache (35%), cranial nerve palsy (31%), seizure (21%), a focal sign such as motor deficit of the limb, frontal syndrome, cerebellar syndrome or aphasia (27%) and signs of cerebral hypertension (3%). The median time between onset of neurological symptoms and diagnosis of CA was 4 days [0-18]. Fourteen patients (11.7%) had no neurological sign at diagnosis.

### **Clinical presentation varied mainly according to *Aspergillus*' route of dissemination to the brain**

Impaired consciousness was more frequent in cases with hematogenous dissemination (53% vs 36%,  $p=0.006$ ), whereas cranial nerve palsy and headache were more frequent in cases of contiguous infection (65% vs 19%,  $p<0.001$  and 65% vs 24%,  $p=0.01$ , respectively).

Neutropenia was present at diagnosis in 18 patients (15%). Comparison between neutropenic and non-neutropenic patients showed no differences, except for fever which was more frequently observed in the neutropenic group (13/18 [72%] vs. 35/101 [35%],  $p=0.004$ ) (table S1).

Comparison of clinical findings according to underlying diseases (HM/SOT/other) showed that fever was rare in SOT patients (5/34 [15%] vs. 26/47 [55%] in the HM group,  $p=0.0002$

and 17/38 [45%] in the remaining population,  $p=0.009$ ) (table S2). Conversely, impaired consciousness was more frequently observed in SOT than in HM patients (22/34 [65%] vs 16/47 [34%],  $p=0.006$ ).

### **Fungal culture, biomarkers and cerebrospinal fluid characteristics**

Considering all the samples analysed (including extracerebral samples such as broncho-alveolar fluid), *Aspergillus* species were identified in 86 patients (table 2). *A. fumigatus* was the most frequent species (88% of all isolates). All *Aspergillus flavus* isolates were found in the contiguous group ( $p=0.004$ ). A concomitant bacterial or fungal infection was diagnosed in 15 and 13 patients, respectively; a detailed description is provided in the supplementary material (table S4).

Sixty-seven patients (56%) had a lumbar puncture at diagnosis. All of the 67 CSF mycological cultures performed were negative, although CSF analysis showed evidence of meningitis in 25/58 cases (43%) (table 1). In cases of meningitis, median CSF WBC count was  $258/\text{mm}^3$  [70-885] with a predominance of polynuclear neutrophils in 76% of samples.

In the sera, 66/104 (64%) of the patients had a positive GM at diagnosis, 15/18 (83%) had a positive  $\beta$ -D-glucan, and 15/27 (56%) a positive *Aspergillus* PCR (Table 2). Median titer of positive GM and of  $\beta$ -D-glucan were 2.25 [1.05-4.7] and 431 ng/ml [188->500], respectively.

In CSF, 31/45 (69%) of patients had a positive GM, 7/11 (64%) a positive  $\beta$ -D-glucan and 14/26 (54%) a positive *Aspergillus* PCR. Median index of the positive GM and  $\beta$ -D-glucan in the CSF were 5 [1.1-7.8] and 359 [194->500], respectively (Table 2). At least one of the three biomarkers of CA was detected in the CSF for 40/53 patients (76%). In 6/18 cases (33%), the GM and *Aspergillus* PCR results were discordant in the CSF. No correlation was found between the presence of meningitis and the detection of GM in the CSF ( $p=0.73$ ).

### **Serum but not CSF biomarkers positivity varied according to *Aspergillus*' route of dissemination**

GM was more frequently detected in the serum of patients in the haematogenous dissemination group than in the contiguous group (55/80 [69%] vs 11/24 [46%],  $p=0.04$ ), as well as in neutropenic patients compared to non-neutropenic patients (15/18 [83%] vs 51/86 [59%]  $p=0.06$ ) (table 2, S1 and S3). In contrast, GM positivity in the serum did not vary significantly according to the underlying disease (Table S3). Positive assays for *Aspergillus* PCR in the serum were found exclusively in patients from the haematogenous dissemination group (n=15/22 [68%] vs 0/5 [0%],  $p=0.01$ ). No differences according to the route of dissemination was found for  $\beta$ -D-glucan.

GM, *Aspergillus* PCR and  $\beta$ -D-glucan positivity in the CSF were similar in the haematogenous dissemination group and in the contiguous infection group (table 2).

### **Brain imaging characteristics**

We were able to recover and analyze diagnostic cerebral imaging for 86 patients: 68 MRI and 18 CT-scan. Good quality imaging exploring the cerebral vessels was available for 53 patients. Radiological findings are displayed in Table 3. Brain abscesses were the most frequent lesion of CA, seen in 76% of the patients. Meningitis was present in 38% of patients. Six cases of ventriculitis were reported (7%), mostly in highly immunocompromised patients (5/6 had HM or SOT). In addition to brain lesions, one patient had a concomitant spinal infection (and 2 others developed a spinal location during the follow-up). Median number of abscesses per patient was 2 [1-4]. Nineteen patients (31% of the patients with abscesses) had a single lesion and 30 (48%) had more than 3. Median size of the main

abscess was 21 mm [15-29]. Abscess wall enhancement was seen in 84% of cases, which did not differ between the haematogenous dissemination and contiguous infection groups, between neutropenic and non-neutropenic patients, or according to the underlying disease (table 3, S2 and S3).

### **Two patterns of radiological lesions were associated with *Aspergillus*' route of dissemination to the brain**

Brain abscesses ( $p < 0.001$ ), particularly multiple ( $> 3$ ) ( $p = 0.02$ ), were more often observed in the haematogenous dissemination group than in the contiguous infection group (Table 3). On the contrary, a contiguous infection was associated with a higher frequency of pachymeningitis ( $p < 0.001$ ) (figure 2). Large vessel disease was more frequently detected in cases of contiguous infection ( $p = 0.01$ ), mainly as the consequence of skull base and cavernous sinus involvement, whereas small vessel disease was more frequently associated with haematogenous dissemination ( $p = 0.002$ ) (figure 2). Occlusion of a large venous sinus was only seen in case of contiguous dissemination, as a consequence of direct vein invasion.

### **Treatment**

In total, 113 patients received antifungal agents. Details regarding the first-line treatments are displayed in Table 4. Eighty-eight patients (74%) received a voriconazole-based first line therapy, either alone ( $n = 49$ ) or in combination with liposomal amphotericin B ( $n = 20$ ) or echinocandins ( $n = 19$ ). A total of 15 adverse events were recorded during voriconazole treatment (corresponding to 15% of the patients who received voriconazole overall), including four cases of hepatitis, four cases of peripheral neuropathy, three cases of



photosensitivity, three cases of periostitis, and one episode of visual hallucinations. These side-effects led to treatment interruption in 9 patients (60%).

Twenty-one patients underwent neurosurgery (two surgical interventions were performed in five patients and three in one) (Table 4). Comparison of clinical and radiological characteristic of operated and non-operated patients did not show any significant difference except for the median number of abscesses (1 [1-2.3] vs 4 [2-10]  $p=0.009$ ) (table S5). The neurosurgical procedures included abscess resection ( $n=16$ ) or drainage ( $n=2$ ), lobectomy ( $n=2$ ), ventricular shunting ( $n=7$ ), and craniotomy/haematoma drainage ( $n=2$ ). Ten patients (48%) experienced at least one complication of the surgical procedure: nosocomial meningitis ( $n=4$ ), intracranial haematoma ( $n=2$ ), oedema with or without intracranial hypertension ( $n=3$ ), pseudomeningocele ( $n=1$ ), and septic shock ( $n=1$ ). None of the patients died following surgery. Ten patients underwent sinus surgery, including sphenoidectomy, ethmoidectomy, and middle meatal antrostomy.

## Outcome

Mortality was 45% at 6 weeks (W6), 51% at 3 months, and 63% at 12 months (M12) (figure 3). W6 mortality was 57%, 73%, 41% and 32% in the HM, HSCT, SOT, and other diseases groups, respectively (table S2). W6 and M12 mortality varied significantly according to the route of dissemination (54% vs 19% at W6 in the haematogenous dissemination and contiguous groups, respectively,  $p<0.001$  and 69% vs 46% at M12,  $p=0.04$ ). The use of voriconazole as first-line treatment was associated with a better outcome at W6 (39% mortality at W6 in the voriconazole group vs 63% in others,  $p=0.02$  but not at M12 (51% mortality vs 59% at M12,  $p=0.5$ ). In univariate analysis, HM, neutropenia, haematogenous dissemination, shorter time to diagnosis, and the detection of GM in serum were associated

with a significantly lower six-week survival (table 5). After variable selection and correction for optimism, haematogenous dissemination, HM, and positive GM in the sera were predictive of W6 mortality.

## Discussion

This large nationwide retrospective study provides new insights into the clinical, mycological, and radiological features of CA. We were able to characterize two different patterns of CA according to the presumed route of dissemination, reflecting several differences in brain infection pathophysiology.

Infection of the brain following haematogenous dissemination was seen in younger patients, most often with HM or SOT. In this population, GM and *Aspergillus* PCR were often positive in serum as well as in the CSF; the main radiological abnormalities were cerebral abscesses, often numerous and associated with small vessel disease. Progression of the disease was rapid, and associated with a high mortality. On the other hand, extension of a contiguous paranasal infection to the brain was seen in older and less immunosuppressed patients. GM and *Aspergillus* PCR were often negative in serum, but positive in the CSF. The main radiological abnormalities were a single abscess with frequent pachymeningeal involvement and large vessel disease, resulting in a high frequency of ischemic events. Progression of the disease appeared slower and associated with a lower mortality rate.

These observations have important implications for CA diagnosis, management and prognosis evaluation. Regarding diagnosis, two points should be emphasised. First, the low positivity rate of serum GM and *Aspergillus* PCR in patients with a contiguous infection suggests a limited release of *Aspergillus* DNA and cell wall components in blood. This is in accordance with the rarity of extracerebral aspergillosis in this group. Therefore, diagnosis of


this form of CA should not only rely on serum fungal biomarkers, but also on CSF biomarkers which should be measured in all suspected cases when feasible. Given the discordance observed between GM and PCR results in CSF, we recommend the determination of both. One should also bear in mind that a normal CSF analysis cannot be used to exclude the diagnosis of CA and is not correlated with GM or PCR result. Second, clinical examination was normal for almost 12% of the patients in our study. Based on a retrospective analysis of 29 children with CNS mold infection, the recent paediatric antifungal guidelines of ECIL-8 recommended performing CNS imaging for all children with IA irrespective of neurological symptoms (grade BII) (14,15). Our data further support brain MRI screening of IA patients to ensure the detection of CA as rapidly as possible.

The contiguous extension from a paranasal sinus infection was often associated with angioinvasion of proximal cerebral vessels, whereas hematogenous dissemination was associated with small vessel obstruction, possibly through an embolic process. Both result in a high frequency of ischemic lesions but with different topology. These observations raise questions about the potential benefit of anti-platelet aggregation therapy, particularly in patients with CA resulting from a contiguous sinus infection. A recent study of 41 cases of aspergillus carotidis highlighted the devastating consequences of carotid invasion in patients with localized cranial aspergillosis, with the occurrence of cerebral infarcts in 50% of the patients (16). Vascular imaging such as magnetic resonance image/magnetic resonance angiogram (MRI/MRA) should be performed in patients with CA to allow early detection and specific management of vascular abnormalities.

Finally, we identified HM and the detection of GM in the serum as the two independent prognostic factors for CA. This is clinically valuable because CA-related mortality remains as high as that reported more than 10 years ago (54-69%) (4,8). A lower mortality rate (38% at

M3) was recently reported, but the study included a limited number of patients, half of whom displayed lower levels of immunosuppression (6). In our study, mortality rates were particularly low for the patients who underwent surgery, but, given the retrospective design of the study, it would be risky to draw any firm conclusions from this observation. Indeed, the patients who did and did not undergo surgery were not comparable in terms of their underlying conditions and clinical status. Further studies will be needed to assess the potential impact of neurosurgery, its optimal timing and related morbidity in this fragile population.

This is the largest series of CA cases reported to date. This study has several strengths allowing for correlations and the identification of two distinct pathophysiological patterns. In contrast, its retrospective design entails inevitable limitations. Our conclusions are limited by the heterogeneity of diagnosis strategies and treatment, the non-availability of almost 30% of the imaging results used for diagnosis, as well as by partial information during follow-up (such as the evaluation of sequelae in survivors or the time course of changes in GM levels). Furthermore, this cohort is the result of screening mycological databases and physicians declarations, so it is vulnerable to recall bias which may alter its representativeness. Indeed, one could speculate that physician notifications of CA are predominantly found in cases in which the diagnosis is more obvious. Contrarily, cases which are difficult to diagnose are more likely to not result in any notification. This could result in a bias: only the evident cases are included, which favors the diagnostic tools that make the case so evident. Despite these limitations, however, our data provide physicians with useful insight into the diagnosis, management, and prognosis of CA.



**Figure 1. Flow chart of the mode of CA diagnosis**

CA: cerebral aspergillosis; GM: galactomannan antigen

\* diagnosis on sinus biopsy/surgery required: sinus biopsy with histological evidence of invasive mold infection associated with growth of *Aspergillus* following culture of the biopsied site and imaging showing a contiguous infection from the sinus to the brain.

# among the 65 probable CA, four patients were categorized as “modified probable CA” as diabetes mellitus was their only risk factor for IA.

& among the 44 probable CA without a positive dosage of GM in the CSF

- 12 patients had proven IA and 32 a probable IA in another organ
- Four patients had a positive *Aspergillus* PCR and one patient had a positive  $\beta$ -D-glucan in the CSF




Figure 2. Examples of CNS imaging for patients with aspergillosis following contiguous (A, B, C) and haematogenous (D) spread with examples of macrovascular (E,F) and microvascular (G,H) lesions

A: Coronal CT view of the sphenoid sinus, showing left sphenoid aspergillosis (arrow) and osteolysis of the sphenoid wall (arrowheads).

B: Axial T1-weighted MRI sequence after contrast injection, showing a left sphenoid sinus mass extending into the CNS with a large extra-axial abscess (arrowheads) and left cavernous sinus involvement.


C: Axial T1-weighted MRI sequence after contrast injection, showing a thickening of the left cerebellar tentorium (arrowheads) corresponding to contiguous pachymeningitis

D: Axial T1-weighted MRI sequence after contrast injection, showing multiple annular contrast enhancing lesions (arrows) corresponding to haematogenic abscesses

E: Time-of-flight angiogram in axial view, showing an occlusion of the left carotid artery (arrowhead)

F: Corresponding diffusion-weighted image, showing a hyperintensity corresponding to a brain infarction systematised to the left anterior cerebral artery territory

G and H: Patient presenting a right lenticular lacunar infarct (arrowhead) on a diffusion-weighted sequence (C). The ischemic nature of the lesion is confirmed by the absence of enhancement on the corresponding post-contrast T1-weighted sequence (D)



**Figure 3. Overall mortality at 6 weeks, 3 months and 12 months**

The dashed line indicates the pointwise 95% confidence interval. Three patients were lost to follow-up before three months and 14 were lost to follow-up before 12 months. The median follow-up of survivors was 16.8 months [9-36.7 months].

	Total (n=119)	Haematogenous dissemination (n=88)	Contiguous infection (n=31)	p-value
Age (years) at diagnosis, median and [IQR]	58 [47.5-66.5]	56 [44-62]	68 [55.5-77]	<0.001
Women, n (%)	40 (34%)	30/88 (34%)	10/31 (32%)	0.85
<b>Main underlying diseases</b>				
-Haematological malignancy <sup>o</sup>	47/119 (40%)	39/88 (44%)	8/31 (26%)	0.07
* HSCT	15 (13%)	12 (14%)	3 (10%)	
* median time from HSCT to CA (months)	3 [1-7.15]	4.0 [1.7-7.1]	0.4 [0.2-6.5]	0.3
-Solid organ transplant	34/119 (29%)	29/88 (33%)	5/31 (16%)	0.1
* heart	* 13 (10.9%)	13 (14.7%)	0 (0%)	
* lungs	* 3 (3%)	2 (2%)	1 (3%)	
* kidney	* 11 (9%)	8 (9%)	3 (10%)	
* liver	* 5 (4%)	4 (5%)	1 (3%)	
* double transplant <sup>fl</sup>	* 2 (1.7%)	2 (2%)	0 (0%)	
Median time from SOT to CA (months)	4.3 [2-7.5]	3.3 [1.8-7.4]	7.7 [6.2-17.8]	<b>0.03</b>
-Diabetes mellitus	10/119 (8%)	4/88 (5%)	6/31 (19%)	<b>0.02</b>
-Auto-immune disease	8/119 (7%)	6/88 (7%)	2/31 (6%)	1
-Other <sup>s</sup>	11/119 (9%)	7/88 (8%)	4/31 (13%)	0.5
<b>Underlying disease</b>				
Patients with 2 risk factors	23/119 (19%)	21/88 (24%)	2/31 (7%)	<b>0.04</b>
No underlying disease	9/119 (8%)	3/88 (3%)	6/31 (19%)	<b>0.009</b>
Immunosuppressive drugs <sup>®</sup>				
- corticosteroids	62/119 (52%)	55/88 (63%)	7/31 (23%)	<0.001
- T-cell immunosuppressive	85/119 (71%)	69/88 (78%)	16/31 (52%)	<b>0.004</b>
* ibrutinib	10/119 (8%)	10/88 (11%)	0/31 (0%)	0.06
Neutropenia at diagnosis	18/119 (15%)	13/88 (15%)	5/31 (16%)	0.86
Lymphopenia at diagnosis	70/100 (70%)	54/71 (76%)	16/29 (55%)	<b>0.02</b>
Hypoalbuminemia	56/80 (70%)	45/60 (75%)	11/20 (55%)	0.23
<b>Clinical signs</b>				
Fever	48/119 (40%)	32/88 (36%)	16/31 (52%)	0.14
Headache	41/119 (34%)	21/88 (24%)	20/31 (65%)	<0.001
Impaired consciousness	67/119 (56%)	56/88 (64%)	11/31 (36%)	<b>0.01</b>
Seizure	25/119 (21%)	22/88 (25%)	3/31 (10%)	0.08
Focal sign	41/119 (34%)	33/88 (38%)	8/31 (26%)	0.2
Cranial nerve palsy	37/119 (31%)	17/88 (19%)	20/31 (65%)	<0.001
Normal neurological	14/119 (11.8%)	10/88 (11%)	4/31 (13%)	0.7



<b>examination</b>				
<b>Median time between onset of symptoms and diagnosis (day) [IQR] (n=108):</b>	4 [0-18]	2 [0-9]	54 [16-126]	<b>&lt;0.001</b>
<b>Extra-cerebral location of infection :</b>	104/119 (87%)	74/88 (84%)	30/31 (97%)	0.07
- lung	72	71	1 <sup>#</sup>	
- sinus	29	0	29	
- skin	4	4	0	
- spleen	4	4	0	
- muscle	3	3	0	
- extracerebral vessel	3	2	1 <sup>#</sup>	
- kidney	3	3	0	
- bone	3	2	1 <sup>#</sup>	
- liver	2	2	0	
- endocarditis	2	2	0	
<b>CSF characteristics (67 lumbar punctures)</b>				
<b>High CSF protein levels (<math>\geq 0.4</math> mg/mL)</b>	39/52 (75%)	26/39 (67%)	13/13 (100%)	<b>0.03</b>
<b>Meningitis (WBC<math>&gt;5/mm^3</math>) (n=58)</b>	25/58 (43%)	16/44 (36%)	9/14 (64%)	0.12
<b>Median WBC count in cases of meningitis [IQR]</b>	258 [70-885]	270 [41-872]	258 [80-885]	0.6
<b>Predominance of polynuclear neutrophils in the CSF</b>	19/23 (82%)	14/15 (93%)	5/8 (63%)	0.1
<b>Outcome</b>				
<b>6-weeks mortality</b>	53/118 (45%)	47/87 (54%)	6/31 (19%)	<b>&lt;0.001</b>
<b>12-month mortality</b>	66/105 (63%)	54/79 (69%)	12/26 (46%)	<b>0.04</b>

**Table 1. Clinical and biological characteristics of patients at diagnosis, by route of disease dissemination**

HM : haematological malignancy; HSCT : haematologic stem cell transplant; SOT : solid organ transplant; CSF : cerebro-spinal fluid; WBC : white blood count

<sup>◊</sup> Haematological malignancy included acute leukaemia (13 cases of myeloid leukaemia and 7 of lymphoblastic leukaemia), chronic lymphoid leukaemia (13 patients), lymphoma (11 patients), and 3 other bone marrow disorders (one case of haemophagocytic syndrome, one of bone marrow primary aplasia, and one of myelodysplastic syndrome)

<sup>¶</sup> One patient had a heart and liver transplant and another had a lung transplant followed by a liver transplant

<sup>§</sup> other: HIV infection (n=2), post-surgery (n=3), cirrhosis (n=3), neoplasia (n=1), ARDS (n=1), primary immunodeficiency (n=1)

<sup>&</sup> received in the 6 months preceding CA

<sup>#</sup> all these extra-cerebral locations were reported in the same patient. The only extra-cerebral location reported in 29/31 patients of the contiguous group was the sinuses or the ears.

Of note, all patients under ibrutinib treatment had HM.

	Total (n=119)	Haematogenous dissemination (n=88)	Contiguous infection (n=31)	p-value
<b>Positive culture*</b>	86/119 (72%)	60/88 (69%)	26/31 (84%)	0.09
- <i>A. fumigatus</i>	76/86 (88%)	54/60 (90%)	22/26 (85%)	<b>0.004</b>
- <i>A. flavus</i>	4/86 (5%)	0	4 (15%)	
- <i>A. nidulans</i>	5/86 (6%)	5 (8%)	0	
- <i>A. terreus</i>	1 (1%)	1 (2%)	0	
- <i>Aspergillus. sp</i>	1 (1%)	1 (2%)	0	
<b>Serum analysis</b>				
<b>Positive GM (&gt;0.5)</b>	66/104 (64%)	55/80 (69%)	11/24 (46%)	<b>0.04</b>
<b>Median index of the positive GM</b>	2.25 [1.05-4.7]	2.8 [1.1-4.99]	0.86 [0.57-1.37]	<b>0.003</b>
<b>Positive <math>\beta</math>-D-glucan (&gt;80 pg/ml)</b>	15/18 (83%)	8/10 (80%)	7/8 (88%)	1
<b>Median index of the positive <math>\beta</math>-D-glucan</b>	431 [188->500]	431 [148->500]	377 [249.8->500]	0.94
<b>Positive <i>Aspergillus</i> PCR</b>	15/27 (56%)	15/22 (68%)	0/5 (0%)	<b>0.01</b>
<b>CSF analysis (67 lumbar punctures)</b>				
<b>Positive GM (&gt;0.5)</b>	31/45 (69%)	25/34 (74%)	6/11 (55%)	0.28
<b>Median index of the positive GM</b>	5 [1.4-7.6]	4.9 [1.1-7.4]	5.6 [3.0-7.9]	0.37
<b>Positive <math>\beta</math>-D-glucan</b>	7/11 (64%)	4/7 (57%)	3/4 (75%)	1
<b>Median index of the positive <math>\beta</math>-D-glucan</b>	359.5 [194-475.5]	277.5 [151.5-426.5]	408.5 [362-454]	0.5
<b>Positive <i>Aspergillus</i> PCR</b>	14/26 (54%)	10/18 (56%)	4/8 (50%)	1
<b>Positive for at least one biomarker</b>	40/53 (76%)	32/40 (80%)	8/13 (62%)	0.26

**Table 2. *Aspergillus* spp. identification and biomarkers, by route of disease dissemination**

GM: galactomannan antigen, CSF: cerebrospinal fluid

\* including all positive cultures from cerebral biopsies/surgeries, sinus biopsies, lung biopsies, bronchoalveolar liquid, skin, liver, muscle or arterial vessel biopsies

	Total (n=86)	Haematogenous dissemination (n=59)	Contiguous infection (n=23)	p-value
<b>Number of imaging available for analysis :</b>				
- MRI	68	49	19	
- CT-scan	18	14	4	
<b>Abscesses</b>	62/82 (76%)	56/59 (95%)	6/23 (26%)	<b>&lt;0.001</b>
- number of abscesses				
* 1	19/62 (31%)	15 (27%)	4 (67%)	
* 2-3	14/62 (23%)	11 (20%)	2 (33%)	
* 4-9	15/62 (24%)	15 (27%)	0	
* ≥10	15/62 (24%)	15 (27%)	0	
<b>Location of abscesses</b>				
- supratentorial	40/62 (65%)	34/56 (60%)	6/6 (100%)	0.08
- infratentorial	4/62 (6%)	4/56 (7%)	0	
- both	18/62 (29%)	18/56 (32%)	0	
<b>Median size of the largest abscess, mm [IQR]</b>	21 [15-29.7]	21 [14-29.2]	24.5 [21.7-35.5]	0.3
<b>Abscess wall enhancement</b>	47/56 (84%)	41/50 (82%)	6/6 (100%)	0.6
<b>Radiological meningitis</b>	31/82 (38%)	12/59 (20%)	19/23 (83%)	<b>&lt;0.001</b>
* leptomeningitis	11/82 (13%)	8/59 (14%)	3/23 (13%)	
* pachymeningitis	28/82 (34%)	7/59 (12%)	21/23 (91%)	
<b>Ventriculitis</b>	6/82 (7%)	3/59 (5%)	3/23 (13%)	0.34
<b>Large vessels disease</b>	19/53 (36%)	8/35 (23%)	11/18 (61%)	<b>0.01</b>
- arterial stenosis/occlusion	14/53 (26%)	4/35 (11%)	10/18 (56%)	
- cerebral ischemia	20/81 (25%)	12/59 (20%)	8/22 (36%)	
- aneurysm	1/53 (2%)	0/35 (0%)	1/18 (6%)	
<b>Small vessel disease</b>	31/74 (42%)	29/56 (52%)	2/18 (11%)	<b>0.002</b>
- haematoma	11/84 (13%)	11/62 (18%)	0/22 (0%)	
- micro-bleeding ≥5	9/59 (15%)	9/45 (20%)	0/14 (0%)	
- small subcortical infarct	21/67 (31%)	19/49 (39%)	2/18 (11%)	
<b>Thrombophlebitis</b>	3/81 (4%)	0/58 (0%)	3/23 (13%)	<b>0.02</b>
<b>Cavernous sinus infiltration</b>	7/81 (9%)	1/58 (2%)	6/23 (26%)	<b>0.001</b>

**Table 3. Radiological characteristics, by route of disease dissemination**

Neuroimaging was performed in all patients at diagnosis, but was available for analysis in 86 patients (72.3%): MRI for 68 patients and CT-scans for 18 patients.

	Total (n=119)	Haematogenous dissemination (n=88)	Contiguous infection (n=31)
<b>Medical treatment</b>			
<b>Voriconazole</b>	88/119 (73.9%)	54/88 (61%)	24/31 (77%)
• alone	49/119 (41%)	33/88 (38%)	16/31 (52%)
• in dual therapy :	39/119 (33%)	21/88 (24%)	8/31 (26%)
- With L-Amb	20/119 (17%)	12/88 (14%)	8/31 (26%)
- With echinocandins	19/119 (16%)	19/88 (22%)	0/31 (0%)
<b>L-Amb</b>	22/119 (18%)	15/88 (17%)	7/31 (23%)
• alone	15/119 (13%)	10/88 (11%)	5/31 (16%)
• in dual therapy :	7/119 (6%)	5/88 (6%)	2/31 (6%)
- With echinocandins	4/119 (3%)	3/88 (3%)	1/31 (3%)
- With posaconazole	2/119 (2%)	1/88 (1%)	1/31 (3%)
- With 5FC	1/119 (1%)	1/88 (1%)	0/31 (0%)
<b>Caspofungine alone</b>	2/119 (2%)	2/88 (2%)	0/31 (0%)
<b>Unknown antifungal treatment</b>	1/119 (1%)	1/88 (1%)	0/31 (0%)
<b>Surgical treatment</b>			
<b>Neuro-surgery</b>	21/119 (18%)	12/88 (14%)	9/31 (29%)
<b>Complication following neuro-surgical procedures</b>	10/21 (48%)	6/12 (50%)	4/9 (44%)

**Table 4. Medical and surgical treatment received, by route of disease dissemination**

NB : 6 patients did not receive anti-fungal therapy because the diagnosis was made post mortem

Variable	Univariate analysis	Multivariate analysis	Prediction model
Age at diagnosis (y)	1.00 (0.98 to 1.02)	1.01 (0.99 to 1.04)	—
Sex (male)	1.58 (0.72 to 3.51)	1.92 (0.78 to 4.72)	—
Haematogenous dissemination	4.89 (1.79 to 13.4)	3.62 (1.04 to 12.6)	2.44 (1.23 to 4.85)
Haematological malignancy	2.86 (1.04 to 7.85)	1.95 (0.61 to 6.25)	1.84 (1.06 to 3.19)
Solid organ transplant	1.48 (0.50 to 4.34)	0.84 (0.26 to 2.71)	—
Neutropenia	2.18 (0.76 to 6.20)	1.55 (0.41 to 5.91)	—
Time from 1 <sup>st</sup> symptoms to diagnosis (weeks)	0.89 (0.80 to 0.98)	0.96 (0.88 to 1.05)	—
Positive GM in serum	2.84 (1.21 to 6.63)	2.15 (0.82 to 5.66)	2.07 (1.14 to 3.76)

**Table 5. Factors associated with six-week mortality. The results presented are odds ratios and 95% confidence intervals.** For the selected model, shrunken coefficients (corrected for optimism) are presented. All estimates are pooled over imputed datasets, data being missing for time from 1<sup>st</sup> symptoms to diagnosis (n = 11) and positive GM in serum (n = 15).

**CEREALS article – supplementary material****Methods - Statistical analysis**

Data are reported as counts and percentages for categorical data, and as the mean and standard deviation (SD) or median and interquartile range (IQR) for quantitative data. Follow-up was counted from the date of diagnosis to the date of death or last contact with the living patient. For patients diagnosed at autopsy, survival was set to zero. Overall survival was estimated by the Kaplan-Meier product-limit method. The primary outcome was three-month mortality. We accounted for patients for whom data were censored before three months of follow-up (which was the case for two patients), by weighting for the inverse probability of censoring (12). Missing baseline data were handled by multiple imputations, with chained equations, using the baseline cumulative hazard of failure in the imputation model (18). All variables considered for model development were used in the imputation model, together with the cohort, and the cumulative hazard (19). We generated and separately analysed 10 independent imputed datasets (20). The convergence of the multiple imputation algorithm was assessed by visual inspection of the mean and variance of the imputations streams. Estimates were then pooled over the 10 imputations according to Rubin's rules, to obtain point estimates and confidence intervals (CI) for each parameter. Logistic regression was used to estimate the association of a set of predefined variables (age at diagnosis, sex, underlying disease, neutropenia at diagnosis, time from first symptoms to diagnosis and positive GM in serum) and three-month mortality, after weighting to correct for censoring. For continuous variables, restricted cubic splines were used to display the shape of the relationship, and variables were then transformed. Given the small number of

events, we used three strategies for model development with the imputed data (21,22). We first used Wald tests for the pooled regression coefficients, to simplify the model with a backward selection procedure, with  $p$ -value cut-offs mimicking the use of the Akaike information criterion (AIC). We then used a similar backward elimination procedure on each imputed dataset and evaluated the proportion of imputed datasets in which the variables were selected. Finally, we used lasso regularisation to fit a final model, with a penalty factor determined by cross-validation. The lasso method has the advantage of selecting the model by shrinking coefficients to zero. Model performance was evaluated by calculating the concordance ( $c$ ) statistic, as a measurement of discrimination, and Brier score, and from the calibration curve. The  $c$  statistic quantifies how well the model discriminates between the patients who die and those who survive, and corresponds to the area under the receiver operating characteristics (ROC) curve in the case of binary outcomes (23). It ranges from 0.5 to 1.0, with 1.0 indicating perfect discrimination. The Brier score is a measurement of overall performance. It ranges from 0 (perfect prediction) to 1 (poorest prediction). It is usually compared to the Brier score of the null model (without predictors), and should be lower. The calibration curve can be used to contrast the observed and predicted probabilities of an event, to evaluate the accuracy of model predictions. Performance was assessed by calculating the parameters for all the imputed dataset and then pooling (impute-last method), as previously recommended (24). Prognostic models derived from multivariable regression with variable selection are prone to overestimating regression coefficients; we therefore performed an internal validation of our model by bootstrapping (23). The second strategy for model selection was repeated in 200 bootstrap samples, and the model estimated from each bootstrap sample was then evaluated in the original sample. The differences between the performance on the bootstrap sample and that on the original

sample were used to assess the overoptimism of the selected model. The *c* statistic, corrected for overoptimism was then estimated, and the slope of the calibration curve was used as a shrinkage factor for the regression coefficients of the selected model. This shrinkage factor was compared with the shrinkage factor obtained by the lasso method. In each case, the predictions and the estimation of model performance were calculated for the imputed datasets and then pooled (impute-last method), as previously recommended (24). The final model is presented with the odds ratios obtained after shrinkage and their 95% confidence intervals (95% CI), together with a nomogram to facilitate the calculation of prediction score. All tests were two-tailed, and *P* values of 0.05 or below were considered to be statistically significant. Analyses were performed with R statistical software version 3.6.1.

## Supplementary results

### Comparison of sub-populations

	Non neutropenic patients (n=101)	Neutropenic patients at diagnosis (n=18)
<b>Clinical signs</b>		
Fever	35/101 (35%)	<b>13/18 (72%)</b>
Headache	34/101 (34%)	7/18 (39%)
Impaired consciousness	56/101 (55%)	11/18 (61%)
Seizure	20/101 (20%)	5/18 (28%)
Focal sign	34/101 (34%)	7/18 (39%)
Cranial nerve palsy	28/101 (28%)	9/18 (50%)
Normal neurological examination	13/101 (13%)	1/18 (6%)
<b>Microbiological characteristics</b>		
Biological meningitis (WBC>5/mm <sup>3</sup> )	24/49 (49%)	1/9 (11%)
Positive GM in the sera	51/86 (59%)	15/18 (83%)
<b>Radiological characteristics</b>		
Abscesses	55/71 (78%)	7/11 (64%)
Contrast enhancement	42/50 (84%)	5/6 (83%)

Meningitis	27/71 (38%)	4/11 (36%)
Ventriculitis	5/71 (7%)	1/11 (9%)
Macro-angiopathy	16/47 (34%)	3/6 (50%)
Micro-angiopathy	28/64 (44%)	3/10 (30%)
<b>Mortality</b>		
Mortality at 6 weeks	42/100 (42%)	11/18 (61%)
Mortality at 12 months	53/90 (59%)	13/15 (87%)

**Table S1. Comparison of clinical and radiological characteristics of neutropenic versus non neutropenic patients at diagnosis**

GM: galactomannan antigen, WBC: white blood count

	<b>HM (n=47)</b>	<b>SOT (n=34)</b>	<b>Other (n=38)</b>
Age (years) at diagnosis, median and [IQR]	61 [44.5-67]	58 [44.5-67]	57 [48-72.8]
Number of Female (%)	19 (40%)	11 (32%)	10 (26%)
Hematogenous dissemination	39/47 (83%)	29/34 (85%)	20/38 (53%)
<b>Clinical signs</b>			
Fever	<b>26/47 (55%)</b>	<b>5/34 (15%)</b>	<b>17/38 (45%)</b>
Headache	15/47 (32%)	9/34 (27%)	17/38 (45%)
Impaired consciousness	<b>16/47 (34%)</b>	<b>22/34 (65%)</b>	19/38 (50%)
Seizure	11/47 (23%)	6/34 (18%)	8/38 (21%)
Focal sign	21/47 (45%)	10/34 (29%)	10/38 (26%)
Cranial nerve palsy	12/47 (26%)	12/34 (35%)	13/38 (34%)
Normal neurological examination	6/47 (13%)	4/34 (12%)	4/38 (11%)
<b>Biological characteristics</b>			
Neutropenia at diagnosis	16/47 (34%)	1/34 (3%)	1/38 (2.6%)
Lymphopenia at diagnosis (n=100)	27/39 (69%)	27/31 (87%)	16/30 (50%)
Hypoalbuminemia (n=80)	20/32 (63%)	19/25 (76%)	17/23 (74%)
Biological meningitis (WBC>5/mm <sup>3</sup> ) (n=58)	10/26 (39%)	8/18 (44%)	7/14 (50%)
Positive GM in the sera (n=104)	25/42 (60%)	24/31 (75%)	17/31 (55%)
<b>Radiological characteristics</b>			
Abscesses	22/28 (79%)	25/29 (86%)	15/25 (60%)
Contrast enhancement	15/20 (75%)	19/22 (86%)	13/14 (93%)
Meningitis	8/28 (29%)	9/29 (31%)	14/25 (56%)
Ventriculitis	2/28 (7%)	3/29 (10%)	1/25 (4%)



Macro-angiopathy	5/18 (28%)	7/17 (41%)	7/18 (39%)
Micro-angiopathy	9/27 (33%)	16/30 (53%)	6/17 (41%)
<b>Mortality</b>			
Mortality at 6 weeks	27/47 (58%)	14/34 (41%)	12/37 (30%)
Mortality at 12 months	30/41 (73%)	17/31 (55%)	19/33 (58%)

**Table S2. Comparison of clinical and radiological characteristics of the patients according to their underlying diseases :**

HM: haematological malignancy , SOT: solid organ transplant , GM: galactomannan antigen  
Other includes : diabetes (n=10), autoimmune diseases (n=8), HIV infection (n=2), post-surgery (n=3), cirrhosis (n=3), neoplasia (n=1), ARDS (n=1), primary immunodeficiency (n=1) and no underlying disease (n=9)

	HM	SOT	Diabetes	Auto-immune diseases	Other risk factors	No risk factor	total
<b>Serum GM positivity</b>	25/42 (59.5%)	24/31 (77.4%)	2/8 (25%)	5/7 (71.4%)	5/8 (62.5%)	5/9 (55.5%)	66/104 (63.5%)

**Table S3. Galactomannan positivity at diagnosis according to the underlying disease**

HM: haematological malignancy , SOT: solid organ transplant , GM: galactomannan antigen

### Concomitant infections

A systemic bacterial co-infection was diagnosed in 15 (12.6%) patients, predominantly involving Gram-negative bacteria (4 among the proven CA and 11 among the probable CA).

A invasive fungal concomitant infection was diagnosed in 13 patients (10.9%) (including 4 with a proven CA and 9 with a probable CA). Twelve of the 13 patients were in the HM and SOT groups (12/13). The co-infection was documented in the brain in only one patient (Mucorales). Ten patients (8.4%) had CMV reactivation, but none displayed any evidence of CMV disease.

	Fungus identified	Localization of the concomitant fungal infection	Diagnosis method of CA	Outcome
Patient 1	<i>Pneumocystis</i>	Lungs	proven	Alive at S6
Patient 2	<i>Mucorales</i>	Kidney	proven	Alive at S6
Patient 3	<i>Candida (C. albicans)</i>	Blood and ascites	probable	Deceased
Patient 4	<i>Candida (C. krusei)</i>	Blood	probable	Deceased
Patient 5	<i>Candida (C. krusei)</i>	Blood	probable	Deceased
Patient 6	<i>Candida sp</i>	Peritoneum	probable	Alive at S6
Patient 7	<i>Pneumocystis</i>	Lungs	proven	Alive at S6
Patient 8	<i>Trichosporon mycotoxinivorans</i> and <i>Scedosporium apiospermum</i>	T : blood, heart and lungs S : lungs, heart, liver, intestine, kidney	probable	Deceased
Patient 9	<i>Candida (C. albicans)</i>	Blood	probable	Deceased
Patient 10	<i>Mucorales (Rhizomucor)</i>	Brain	proven	Deceased
Patient 11	<i>Candida (C.krusei)</i>	Blood	probable	Deceased
Patient 12	<i>Mucorales (rhizomucor)</i>	Pleura	probable	Deceased
Patient 13	<i>Mucorales (Rhizopus)</i>	Lungs	probable	Deceased

Table S4. Fungal co-infections and associated outcome.

## Treatment

Twenty-one patient underwent neuro-surgery. Main characteristics of operated on patients are displayed in table S5.

	Surgery (n=21)	No surgery (n=98)
Median age (years)	54 [39-62]	59 [48.25-67]
Underlying context		
- HM	6/21 (29%)	41/98 (42%)
- SOT	4/21 (19%)	30/98 (31%)
- Other	11 /21(52%)	27/98 (28%)
Haematogenous dissemination	12/21 (57%)	76/98 (78%) <sup>o</sup>
Neutropenia at diagnosis	1/21 (5%)	17/98 (17%)
Radiological findings:		
- abscesses	12/12 (100%)	50/70 (71%)
* median number of abscesses	1 [1-2.3]	4 [2-10] <sup>s</sup>
* size of the largest abscess	24 mm [19-31]	21 mm [14-29]
- meningitis	6/12 (50%)	25/70 (36%)
- microangiopathy	3/10 (30%)	28/64 (44%)
- macroangiopathy	0/7 (0%)	19/46 (41%)
6-week mortality	2/21 (10%)	51/97 (53%)

**Table S5. Characteristics of the patients who underwent surgical procedures**<sup>◇</sup> p=0.053<sup>§</sup> p=0.009

HM: haematological malignancy, SOT: solid organ transplant

**Outcome**

The six-week mortality was 15/55 (27.3%) and 38/64 (59.3%) for proven and probable CA, respectively. In most studies IFI proven cases mortality is higher than probable cases. In our study, several particularities may explain this result. Diagnosis of proven CA requested either a cerebral biopsy or a sinus biopsy (with a contiguous infection): the most critically ill patients, or the one who died rapidly didn't have a cerebral biopsy; sinus biopsy meant a contiguous infection of the brain from a paranasal sinus, which is associated with a better outcome.

We divided the inclusion period into 3 equally-sized categories (with cut points at November, 2012 and June, 2015). Adjusted for the final model, W6 mortality did not change significantly over the study period :

- Odd ratio of 0.90 (0.44 to 1.84) for period 2 (between Nov 2012 and June 2015) compared to 1 (before Nov 2012)
- Odd ratio of 0.85 (0.40 to 1.77) for period 3 (after June 2015) compared to 1 (before Nov 2012)

**Study funding**

No external funding was received for the conduction of this study.

**Acknowledgement:** we thank Dr Olivier Paccoud for his careful rereading of this article.

**Author's contribution**

FL and OL coordinated the work of the authors and guided the development of the study. AS and FD collected the cases, and wrote the initial manuscript draft. JB and ON reviewed all brain imaging. Statistical analyses were performed by AS and RP. Other authors (RS, MW, SK, VL, AF, GH, VP, M-EB, SP, FA, FP, FC, PT, J-PG, LL, SC, FB, SH, SB, RH) critically revised the draft and added important intellectual content. All authors participated in review and revisions, approved the final manuscript and are accountable for all aspects of the work and for ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. All authors had access to and verified the data here presented.

**Conflict of interest disclosure**

Dr Serris, Dr J. Benzakoun, Dr R. Porcher, Dr G. Hekimian, Dr L. Lelièvre, Dr F. Bonneville, Dr M-E. Bounoux, Dr S. Houze, Dr S. Bretagne, Dr S Kremer, Dr V Letscher-Bru, Dr V. Pourcher, Dr S. Poirée, Dr FA, Dr P. Tattevin have nothing to declare.

Dr. Danion reports personal fees from Gilead, outside the submitted work.

Dr F. Cotton declares personal fees from Bayer Schering, Biogen IDEC, Bracco imaging, Guerbet, Novartis outside the submitted work.

Dr M. Wolff declares lectures fees from MSD and from Correvio outside the submitted work.

Dr A. Fekkar declares personal fees from Gilead, MSD, Pfizer and Janssen, outside the submitted work.

Dr. Gangneux reports personal fees from Pfizer, personal fees from Gilead, outside the submitted work.

Dr. Cassaing reports non-financial support and other from Gilead Sciences, non-financial support and other from Pfizer France, non-financial support and other from MSD france, outside the submitted work.

Dr. Kremer reports personal fees from biogen, personal fees from alexion, personal fees from roche, personal fees from bayer, outside the submitted work.

Pr. Lanternier reports personal fees from Gilead, F2G outside the submitted work.

**Bibliography**

1. Miceli MH. Central Nervous System Infections Due to *Aspergillus* and Other Hyaline Molds. *J Fungi*. 30 août 2019;5(3):79.
2. Candoni A, Klimko N, Busca A, Di Blasi R, Shadrivova O, Cesaro S, et al. Fungal infections of the central nervous system and paranasal sinuses in onco-haematologic patients. Epidemiological study reporting the diagnostic-therapeutic approach and outcome in 89 cases. *Mycoses*. mars 2019;62(3):252-60.
3. Baddley JW, Salzman D, Pappas PG. Fungal brain abscess in transplant recipients: epidemiologic, microbiologic, and clinical features. *Clin Transplant*. déc 2002;16(6):419-24.
4. Kourkoumpetis TK, Desalermos A, Muhammed M, Mylonakis E. Central nervous system aspergillosis: a series of 14 cases from a general hospital and review of 123 cases from the literature. *Medicine (Baltimore)*. nov 2012;91(6):328-36.
5. Antinori S, Corbellino M, Meroni L, Resta F, Sollima S, Tonolini M, et al. *Aspergillus* meningitis: a rare clinical manifestation of central nervous system aspergillosis. Case report and review of 92 cases. *J Infect*. mars 2013;66(3):218-38.
6. Marzolf G, Sabou M, Lannes B, Cotton F, Meyronet D, Galanaud D, et al. Magnetic Resonance Imaging of Cerebral Aspergillosis: Imaging and Pathological Correlations. *PloS One*. 2016;11(4):e0152475.
7. Charlot M, Pialat J-B, Obadia N, Boibieux A, Streichenberger N, Meyronnet D, et al. Diffusion-weighted imaging in brain aspergillosis. *Eur J Neurol*. août 2007;14(8):912-6.
8. Schwartz S, Ruhnke M, Ribaud P, Corey L, Driscoll T, Cornely OA, et al. Improved outcome in central nervous system aspergillosis, using voriconazole treatment. *Blood*. 15 oct 2005;106(8):2641-5.
9. Marr KA, Schlamm HT, Herbrecht R, Rottinghaus ST, Bow EJ, Cornely OA, et al. Combination antifungal therapy for invasive aspergillosis: a randomized trial. *Ann Intern Med*. 20 janv 2015;162(2):81-9.
10. Panackal AA, Parisini E, Proschan M. Salvage combination antifungal therapy for acute invasive aspergillosis may improve outcomes: a systematic review and meta-analysis. *Int J Infect Dis IJID Off Publ Int Soc Infect Dis*. nov 2014;28:80-94.
11. Donnelly JP, Chen SC, Kauffman CA, Steinbach WJ, Baddley JW, Verweij PE, et al. Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. *Clin Infect Dis Off Publ Infect Dis Soc Am*. 5 déc 2019;
12. Vock DM, Wolfson J, Bandyopadhyay S, Adomavicius G, Johnson PE, Vazquez-Benitez G, et al. Adapting machine learning techniques to censored time-to-event health record data: A general-purpose approach using inverse probability of censoring weighting. *J Biomed Inform*. 2016;61:119-31.
13. Ghez D, Calleja A, Protin C, Baron M, Ledoux M-P, Damaj G, et al. Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib. *Blood*. 26 2018;131(17):1955-9.

14. Lauten M, Attarbaschi A, Cario G, Döring M, Moser O, Mücke U, et al. Invasive mold disease of the central nervous system in children and adolescents with cancer or undergoing hematopoietic stem cell transplantation: Analysis of 29 contemporary patients. *Pediatr Blood Cancer*. août 2019;66(8):e27806.
15. Groll AH, Pana D, Lanternier F, Mesini A, Ammann RA, Averbuch D, et al. 8th European Conference on Infections in Leukaemia: 2020 guidelines for the diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or post-haematopoietic cell transplantation. *Lancet Oncol*. 31 mars 2021;
16. Little JS, Cheng MP, Hsu L, Corrales CE, Marty FM. Invasive Fungal Carotiditis: A Rare Manifestation of Cranial Invasive Fungal Disease: Case Series and Systematic Review of the Literature. *Open Forum Infect Dis*. oct 2019;6(10):ofz392.
17. Wardlaw JM, Smith EE, Biessels GJ, Cordonnier C, Fazekas F, Frayne R, et al. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. *Lancet Neurol*. août 2013;12(8):822-38.
18. Rubin DB, Schenker N. Multiple imputation in health-care databases: an overview and some applications. *Stat Med*. avr 1991;10(4):585-98.
19. White IR, Royston P. Imputing missing covariate values for the Cox model. *Stat Med*. 10 juill 2009;28(15):1982-98.
20. White IR, Royston P, Wood AM. Multiple imputation using chained equations: Issues and guidance for practice. *Stat Med*. 20 févr 2011;30(4):377-99.
21. Vergouwe Y, Royston P, Moons KGM, Altman DG. Development and validation of a prediction model with missing predictor data: a practical approach. *J Clin Epidemiol*. févr 2010;63(2):205-14.
22. Wood AM, White IR, Royston P. How should variable selection be performed with multiply imputed data? *Stat Med*. 30 juill 2008;27(17):3227-46.
23. Harrell FE, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. *Stat Med*. 28 févr 1996;15(4):361-87.
24. Wood AM, Royston P, White IR. The estimation and use of predictions for the assessment of model performance using large samples with multiply imputed data. *Biom J Biom Z*. juill 2015;57(4):614-32.